This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kempf, D. J.
Right arrow Articles by Marsh, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kempf, D. J.
Right arrow Articles by Marsh, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2006, p. 762-764, Vol. 50, No. 2
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.2.762-764.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Practical Preclinical Model for Assessing the Potential for Unconjugated Hyperbilirubinemia Produced by Human Immunodeficiency Virus Protease Inhibitors

Dale J. Kempf,* Jeffrey F. Waring, David C. Morfitt, Paige Werner, Brian Ebert, Michael Mitten, Bach Nguyen, John T. Randolph, David A. DeGoey, Larry L. Klein, and Kennan Marsh

Global Pharmaceutical Research and Development, Abbott, Abbott Park, Illinois 60064

Received 1 March 2005/ Returned for modification 10 May 2005/ Accepted 7 November 2005

A practical preclinical model for the hyperbilirubinemia produced by human immunodeficiency virus protease inhibitors has been developed. Indinavir and atazanavir produced significant hyperbilirubinemia, whereas amprenavir, the negative control, was indistinguishable from the ritonavir booster dose. This model was used to disqualify an exploratory protease inhibitor from development.

* Corresponding author. Mailing address: Department R4CR, Abbott, 200 Abbott Park Road, Abbott Park, IL 60064. Phone: (847) 937-0324. Fax: (847) 938-2756. E-mail: dale.kempf{at}abbott.com.

Antimicrobial Agents and Chemotherapy, February 2006, p. 762-764, Vol. 50, No. 2
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.2.762-764.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Dekhtyar, T., Ng, T. I., Lu, L., Masse, S., DeGoey, D. A., Flosi, W. J., Grampovnik, D. J., Klein, L. L., Kempf, D. J., Molla, A. (2008). Characterization of a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor, A-790742. Antimicrob. Agents Chemother. 52: 1337-1344 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»